Related references
Note: Only part of the references are listed.Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective
Christopher Ross et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2016)
Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris
R. Gniadecki et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Optimizing anti-TNF treatments in inflammatory bowel disease
Shomron Ben-Horin et al.
AUTOIMMUNITY REVIEWS (2014)
Antidrug antibodies in psoriasis: a systematic review
L. Hsu et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis
J. M. P. A. van den Reek et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Reply to 'Complementary data for long-term infliximab use in psoriasis'
Adam J. Luber et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Long-term durability and dose escalation patterns in infliximab therapy for psoriasis
Adam J. Luber et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions
J. Spertino et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry
J. M. Carrascosa et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis One-Year Follow-up
Stef P. Menting et al.
JAMA DERMATOLOGY (2014)
The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
Sandra Garces et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Survival rate of antitumour necrosis factor- treatments for psoriasis in routine dermatological practice: a multicentre observational study
M. Esposito et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis
Qiang Tong et al.
PHARMACOGENOMICS (2013)
Dose-creep of Infliximab During Psoriasis Treatment: An Observational Study
Christine R. Mehren et al.
ACTA DERMATO-VENEREOLOGICA (2012)
Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
Charlotte L. Krieckaert et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Drug survival rates of biologic treatments in patients with psoriasis vulgaris
A. M. G. Brunasso et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
A. B. Gottlieb et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis
Vito Di Lernia et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2012)
Tolerability and Safety of Biological Therapies for Psoriasis in Daily Clinical Practice: A Study of 103 Italian Patients
Alexandra Maria Giovanna Brunasso et al.
ACTA DERMATO-VENEREOLOGICA (2011)
Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
R. Gniadecki et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Emilie Ducourau et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Direct Comparison of Treatment Responses, Remission Rates, and Drug Adherence in Patients With Rheumatoid Arthritis Treated With Adalimumab, Etanercept, or Infliximab Results From Eight Years of Surveillance of Clinical Practice in the Nationwide Danish DANBIO Registry
Merete Lund Hetland et al.
ARTHRITIS AND RHEUMATISM (2010)
Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort
M. Dalaker et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
Amr A. Saad et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Treatment response to a second or third TNF-inhibitor in RA:: results from the South Swedish Arthritis Treatment Group Register
J. A. Karisson et al.
RHEUMATOLOGY (2008)
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Clinical pharmacokinetics and use of infliximab
Ulrich Klotz et al.
CLINICAL PHARMACOKINETICS (2007)
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
Klaus Bendtzen et al.
ARTHRITIS AND RHEUMATISM (2006)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
Share Paper
